Lamictal tablets 25mg GSK treat epilepsy and prevent bipolar disorder (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Lamotrigine

Ingredient

Composition informationContent
Lamotrigine25mg

Uses

indications

Lamictal medicine are indicated in the following cases:

epilepsy:

adults (over 12 years old): Lamictal is appointed to use combination or single therapy in the treatment

Local epilepsy and all epilepsy, including spasms - convulsions and convulsions in Lennox syndrome - Gastaut.

Children (from 2 to 12 years old): Lamictal is designated to be used in combination or monotherapy in the treatment of local epilepsy and total epilepsy, including spasms - convulsions and seizures in Lennox - Gastaut syndrome.

After controlling epilepsy by combined therapy, combined anti -epileptic drugs and patients continue to use monomers with Lamictal.

Lamictal is indicated to use monomers for typical consciousness.

bipolar disorder:

Adults (from 18 years of age): Lamictal is indicated to prevent temperament changes in patients bipolar disorder , mainly preventing depression.

Pharmacokology

Lamotrigine is an inhibitor of sodium channels of voltage depending on the use. Lamotrigine also inhibits the release of glutamate disease (amino acid plays a major role in the generation of seizures), as well as inhibiting the sudden outbreak of the Glutamate release voltage.

pharmacokinetics

Lamotrigine absorbs quickly and completely from the intestine, initially transformed through the liver is negligible. The drug is associated with plasma protein about 55%; less likely to occupy plasma proteins leading to toxicity.

UDP-Glucuronyl Transferase is enzymes responsible for metabolism of Lamotrigine. Lamotrigine clearance is mainly in the form of metabolism with the next excretion of the substance combined with glucuronid in the urine. Under 10% of the drug is eliminated in the urine in the form of constant. Only about 2% of the metabolic substance of elimination drugs through feces.

Before taking Lamictal tablets 25mg GSK treat epilepsy and prevent bipolar disorder (3 blisters x 10 tablets)

How to use

should swallow both tablets, do not chew or grind.

If the dose cannot be divided into multiple tablets with a lower content for patients (such as for children with epilepsy or patients with liver impairment), the dosage should be used with the nearest low content of the whole pills.

Dosage

Epick treatment:

Adults (over 12 years):

The starting dose in single therapy is 25 mg once a day for 2 weeks, followed by 50 mg once a day for the next 2 weeks.

Then increase the dose, up to 50 to 100 mg every 1 to 2 weeks until the optimal response.

The usual maintenance dose for optimal response is 100 to 200 mg/day, taken once or divided into 2 times. Some patients need to use 500 mg of Lamictal/day to achieve the expected response.

Children (2 years old to 12 years old):

Typical consciousness:

  • week 1-2: 0.3 mg/kg (divided 1 or 2 times).
  • week 3-4: 0.6 mg/kg (divided 1 or 2 times). Valproate:
  • week 1-2: 0.15 mg/kg (1 time/day).
  • week 3-4: 0.3 mg/kg (1 time/day).

    Should be used with phenytoine, carbamazepine, phenobarbital, primidone or with other lamotrigine glucuronide induction drugs:

  • week 1-2: 0.6 mg/kg (divided 2 times).
  • week 3-4: 1.2 mg/kg (divided 2 times). Significant advance of lamotrigine glucuronid:
  • week 1-2: 0.3 mg/kg (divided 1 or 2 times).
  • week 3-4: 0.6 mg/kg (divided 1 or 2 times). Age:

    Lamotrigine has not been studied for monomers in children under 2 years of age or combined treatment in children younger than 1 month old.

    Unknown safety and effectiveness of Lamotrigine in the treatment of local epilepsy in children from 1 month of age to 2 years old. Therefore, it should not be used for lamictal for children under 2 years old.

    bipolar disorder:

    Adults (from 18 years old):

    Additional treatment with lamotrigine glucuronide inhibitors such as valproate:

  • week 1-2: 12.5 mg (oral 25 mg daily).
  • week 3-4: 25 mg (1 time/day). With lamotrigine glucuronide induction drugs in patients who do not use Valproate (should use this dosage with phenytoin, carbamazepine, phenobarbital, primidone or other lamotrigine glucuronide induction drugs):

    week 1-2: 50 mg (1 time/day).

  • week 3-4: 100 mg (divided 2 times/day).
  • week 5: 200 mg (divided 2 times/day). No significant inhibition or induction Glucuronid lamotrigine:
  • week 1-2: 25 mg (1 time/day).
  • week 3-4: 50 mg (divided 1 or 2 times/day). (under the age of 18):

    Do not be indicated because it has not established safety and effectiveness in this age group.

    Patients with renal failure:

    Lamotrigine concentration in plasma does not change significantly in the only dose studies in patients with end -stage renal impairment. However, there is a accumulation of glucuronid metabolites; Should be cautious when treating patients with renal failure.

    Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

    Symptoms of overdose include eyeball vibration, loss of movement air conditioning, reduced consciousness, great epilepsy and coma. Also observed that there is a wide range of QRS complexes on an overdose.

    In case of overdose, patients should be hospitalized and treated appropriately according to clinical manifestations or instructions of the National Poison Control Center if any.

    What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

  • Side Effects

    When using Lamictal, you may experience unwanted effects (ADR).

    Common, very common: ADR> 1/100

  • Skin: Ban on the skin.
  • Mental: irritable, easy to be stimulated.

    Neurological: headache , drowsiness, insomnia, dizziness, tremor. Digestive: Nausea, vomiting, diarrhea .

    Body and on -site: tired.

  • musculoskeletal: joint pain, back pain.
  • Rare, very rare: ADR

  • Skin and subcutaneous tissue: Stevens Johnson syndrome, poisoned epidermal necrosis, hair loss.
  • Hematology: leukopenia, Anemia , thrombocytopenia, lymph nodes, blood cell syndrome. immunity: Hypersensitivity syndrome.
  • Mental: Scrambling, hallucinations, confusion, nightmares.
  • Neurology: loss of movement air conditioning, eyeball vibration, sterile meningitis, dance, external effects, condition Parkinson's disease worsens, increasing the frequency of convulsions.
  • eyes: Song, blurred vision, conjunctivitis.
  • liver: liver dysfunction, liver failure.
  • musculoskeletal: Lupus reactions.
  • Instructions on how to handle ADR

    When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

    Warnings

    Before using the drug you need to read the instructions carefully and refer to the information below.

    contraindicated

    Lamictal drugs for patients who know how to be hypersensitivity to lamotrigine or any ingredients of the drug.

    Be cautious when using

    The skin on the skin usually appears within 8 weeks after starting with lamictal treatment and most of these rashes are light and limited. However, there were also reports on severe hospitalization such as Stevens - Johnson syndrome and epidermal necrosis.

    Be cautious when using drugs for patients with a history of allergies or rashes when using other anti -epileptic drugs.

    Bloody factor syndrome has occurred in patients using Lamictal.

    Symptoms of depression and/or bipolar disorder may appear in epilepsy patients and have evidence of high risk of suicide in epilepsy and bipolar disorders.

    It is necessary to closely monitor the deteriorating clinical signs (including new symptoms) and the risk of suicide in patients using Lamictal to treat bipolar disorders.

    Patients using combined contraceptives in most cases need lamotrigine to maintain higher doses (to double) to achieve maximum treatment response. In addition, Lamictal can also reduce the effectiveness of birth control pills in some patients using hormone -containing preparations along with Lamictal.

    Lamictal inhibits the excretion of renal tubular excretion through the protein oct 2, does not recommend simultaneously with the mainly eliminated substances through the OCT 2 path with a narrow treatment index such as dofetilide.

    The Brugada ECG has been observed in patients taking the drug. Be careful when used in patients with Brugada syndrome.

    Stop using sudden blue blue can cause reaction convulsions. Lamictal dose should be reduced slowly for 2 weeks unless it is necessary to stop sudden for safety reasons (such as rash).

    The ability to drive and operate machinery

    Two studies on volunteers show that drugs affect the delicate visual mobilization, eye movement, sway and subjective sedative impact are not different from placebo.

    Neurological side effects such as dizziness and Song Thi have been reported. Therefore, patients should consider how treatment will affect them before driving or operating machinery.

    Pregnancy

    Data after bringing the drug to the market to record more than 8,700 women who use Lamictal treatment in the first 3 months of pregnancy does not suggest a significant increase in the risk of serious birth defects, although the data from a small number of registered studies have recorded an increase in the risk of single -mouthed deformities while the control of the disease has increased the risk Other serious birth defects after using Lamotrigine.

    Only use Lamictal during pregnancy when the benefits are superior to the risk of the body.

    Physiological changes during pregnancy may affect lamotrigine levels and/or therapeutic effectiveness. There was a report on the reduced lamotrigine concentration during pregnancy. It is advisable to ensure the appropriate clinical management for pregnant women during the time of lamictal.

    The period of breastfeeding

    lamotrigine through breast milk with very changing concentrations, resulting in Lamotrigine concentration in children up to nearly 50% of the mother's concentration.

    Therefore, in some breastfeeding babies, the lamotrigine level in serum reaches the level of pharmacological effects. The benefits of breastfeeding should be considered compared to the risk of side effects in children

    Drug interaction

    drugs that can cause induction or inhibition of glucuronids can affect the clearance of Lamotrigine. Medium or strong touch substances Cytochrome P450 3A4 (CYP3A4), which is also known to cause UDP-Glucuronyl Transferase touch may also increase the metabolism of Lamotrigine.

    Therefore lamotrigine interacts with other anti-epileptic drugs such as Valproate (inhibiting lamotrigine glucuronide) and a group of anti-epileptic drugs that touch the cytochrom P450 enzymes, including UDP-glucuronyl transferase (Phenytoine, Carbamazepine, Phenobarbital, Primidone).

    The use of contraceptives combined causes increased oral lamotrigine's clearance to about 2 times.

    Lamictal inhibits the excretion of renal tubular excretion through the protein oct 2, does not recommend simultaneously with the mainly eliminated substances through the OCT 2 path with a narrow treatment index such as dofetilide.

    Storage

    Do not store more than 30 ° C. Store in a dry place.

    Other drugs

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    count views

    Popular Keywords